% | $
Quotes you view appear here for quick access.

Ship Finance International Limited Message Board

  • madmax_194752 madmax_194752 Apr 29, 2013 11:22 AM Flag

    o/t QCOR not a good report-nice divi 3.4%

    Most analysts see a bright future for Questcor. On April 17, 2013, Bank of America/Merrill Lynch rated Questcor as a "Buy" with a $40.00 price target over the next year. On April 8, 2013, Favus Institutional Research downgraded Questcor from a "Buy" to a "Sell," expressing concerns about Questcor's Q1 results. On March 12, 2013, Roth Capital reiterated its "Buy" rating for Questcor after the company released an abstract focusing on Acthar as a first-line treatment for multiple sclerosis, Roth Capital believes the data shows that Acthar is much more potent than ordinary steroids. On March 1, the Jefferies Group maintained their "Buy" rating for Questcor and increased their price target for the company's stock to $38 up from $30. On February 21, 2013, Janney Montgomery Scott initiated coverage of Questcor with a "Buy" rating and a $40 price target, and Mizuho Securities upgraded Questcor to a "Buy" rating up from a "Neutral" rating. Mizuho also increased their price target for Questcor to $41 up from $28. On February 27, Ladenburg Thalman increased their price target for Questcor to $38, up from $33. The firm has a "Buy" rating for Questcor. On February 21, 2013, The Street upgraded Questcor from a "Hold" rating to a "Buy" rating.

    Despite all the negative news, 2012 was a great year financially for Questcor. The company shipped 6,330 vials of Acthar during the fourth quarter 2012, up 88% compared to 3,360 vials in the year ago quarter. For the full year of 2012, Questcor shipped 20,741 vials of Acthar, up 94% compared to 10,710 vials in 2011.

    According to Questcor, Acthar is most commonly prescribed by physicians as a treatment alternative for patients with certain auto-immune conditions in whom first-line therapies have not provided the intended treatment outcome and an additional FDA-approved treatment alternative is needed. Despite the highly critical Prime Therapeutics study released in December 2012, Questcor claims that insurance coverage for Acthar continues

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • QCOR looking better at $34.00....this is the price they need to get past....previously, once it hit this level, it backed down to $30 or under...if it hold here, $40. is coming.

    • Weird action... QCOR missed 1Q estimates and....

      ...the price went up?! Look at the afterhours volume on 4/30; that's the response to the earnings miss.


    • The above was taken from an article on Sea King Al Pha written by C.R. Jackson. If you're going to read that (mostly a negatively spun rehash of news from last ~8 months) you should also read the most recent article on the same subject by Michael Fuller.

      The second article is much more up to date and contains links to a lot of information that's less than 1 quarter old.

      I'm long QCOR and recommend it to my friends.

      • 1 Reply to feralcomprehension
      • feral,
        Nice move on ACAS today. Thanks for that one. Must have been a new high. Earnings report tomorrow. Maybe should have taken some profit today but I'm hoping we hear some nice comments about reinstatement of the dividend. A new dividend could send it into orbit.

        Only one loser out of 24 today.... SDLP. I can't figure that out. They announced the distribution today... Annual equivalent of yield of 5.6% with future dropdowns and distr increases all but locked in.

        My top gainers today.........
        ACAS +4.23% (earnings tomorrow)
        GLOG +3.20% (sold some)
        TGP +2.68% (solid LNG and Product tanker MLP)
        NTI +2.36% (been some coverage on their refinery being well-placed for US and Canadian crude supplies)
        ALDW +1.77%

        Watching the corn crop? Not much planted in Minnesota and colder, wet weather is expected later this week. An article in the Sunday Mpls star tribune.

16.1701+0.4701(+2.99%)1:06 PMEDT